Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis.

Annals of surgical oncology - 1 Jan 2025

Sierra-Davidson Kailan, Dedeilia Aikaterini, Lawless Aleigha, Sharova Tanya, Kaufman Howard L, Boland Genevieve M, Cohen Sonia

Abstract excerpt

BACKGROUND: Talimogene laherparapvec (T-VEC) is a modified herpes simplex virus type 1 (HSV-1) and the first oncolytic virus to be approved for the treatment of unresectable melanoma. We assessed whether there are tumor-intrinsic genetic factors that are associated with tumor control. METHODS: A single-institution, retrospective analysis of melanoma patients treated with T-VEC was performed. Demographics,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Products
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Herpesvirus 1, Human

Share to Melanoma

Share to Oncolytic Virotherapy

Share to Skin Neoplasms

Share to Survival Rate

Share to Telomerase

Source

Open in PubMed Open full text

Identifiers

PMID: 39422848
DOI: 10.1245/s10434-024-16346-x
PMCID: PMC11659343

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis.PMID 39422848Read ↗

Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.Semantic proximity Read ↗

Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.Semantic proximity Read ↗

The impact of melanoma genetics on treatment response and resistance in clinical and experimental studiesSemantic proximity Read ↗

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus ImmunotherapySemantic proximity Read ↗

Prognostic value of TERT promoter mutations in conjunctival melanomas in addition to clinicopathological features.Semantic proximity Read ↗

Molecular Genetics of Conjunctival Melanoma and Prognostic Value of TERT Promoter Mutation Analysis.Semantic proximity Read ↗

Virotherapy: cancer gene therapy at last?Semantic proximity Read ↗

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.Semantic proximity Read ↗

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.Semantic proximity Read ↗

Talimogene laherparepvec (Imlygic) for unresectable melanoma.Semantic proximity Read ↗

Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.Semantic proximity Read ↗

ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.